Adc Therapeutics SA (NYSE:ADCT) concluded the trading at $1.81 on Wednesday, May 14 with a rise of 37.12% from its closing price on previous day.
Taking a look at stock we notice that its last check on previous day was $1.32 and 5Y monthly beta was reading 1.546 with its price kept floating in the range of $1.35 and $1.82 on the day. Considering stock’s 52-week price range provides that ADCT hit a high price of $4.32 and saw its price falling to a low level of $1.05 during that period. Over a period of past 1-month, stock came adding 49.59% in its value.
With its current market valuation of $179.52 million, Adc Therapeutics SA is set to declare its quarterly results on 2025-May-13. Analysts are in estimates of 0 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to 0 for current year with estimates of that growing to 0 in next year.
Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of 17.82M. They suggested that in the process company could generate revenue of as low as 17.5M which could climb up to 18.5M to hit a high. The average estimate is representing an increase of 2.37% in sales growth from that of posted by the company in the same quarter of last year. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of 77.5M in current fiscal year, which will be 9.41% more from revenue generated by the company last year.
In contrast, when we review ADCT stock’s current outlook then short term indicators are assigning it an average of 50% Sell, while medium term indicators are categorizing the stock at an average of 50% Sell. Long term indicators are suggesting an average of 50% Sell for it.
According to ratings assigned by 7 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; 3 of them are recommending Adc Therapeutics SA (ADCT) as a Hold, while 4 are in view that stock is a Buy. Recommendation by 0 analysts for the stock is an Underweight while number of those analysts who rated the stock as an Overweight is 0, whereas 0 of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Overweight and that encourages the investors to exploit the opportunity and build their stake up in the company.
Digging deeper we become aware of the PEG ratio of the ADCT stock which is currently positioned at 0. It further provides that stock’s current price level is 34.12% away from its 20-day simple moving average and is 24.86% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 71.79 while volatility remained at 12.17% over the past week which changes to 7.88% when measuring it over the past month. Beta is valued at 1.50, while measure of average true range or ATR is currently at 0.13. In predicting price targets of as low as $7 and as high as $13, analysts are in agreement on assigning the stock over the next 12 months average price target of $8. Stock’s current price level is -286.74% above from estimated low price target while it is -618.23% below the estimated high; and even if the ADCT’s share succeeded to reach the median price of $8, then the outlook of -341.99% could come to the excitement of the investors.
Having a second look at Adc Therapeutics SA (NYSE:ADCT) provides that stock’s average daily trading volume for 3 months was 327.55K, while it jumped to 475700 when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 99.18 million.
The percentage of outstanding shares held by the insiders is 21.60% while it is 54.93% for the institutional holders. The figures also indicate that as of 2025-04-30, number of stock’s short shares was 4.47 million which implies a short ratio of 13.63. This shows up a 573.00 of Short Interest in company’s outstanding shares on the day. In April the standing of shares short improved as it was 4.29 million in the previous month. Subtraction of -9.05% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.
